Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
AuthorsStallone G, Infante B, Grandaliano G, Bristogiannis C, Macarini L, Mezzopane D, Bruno F, Montemurno E, Schirinzi A, Sabbatini M, Pisani A, Tataranni T, Schena FP, Gesualdo L,
JournalNephrol Dial Transplant
PubMed ID22785114
Background Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of cystic kidney disease. An inappropriate stimulation of mammalian target of rapamycin may represent the converging point in the molecular pathways leading to renal cyst growth. Methods The primary objectives of this prospective, open-label, randomized clinical trial were ... More
Differences in Mammalian target of rapamycin gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity.
AuthorsTchetina EV, Poole AR, Zaitseva EM, Sharapova EP, Kashevarova NG, Taskina EA, Alekseeva LI, Semyonova LA, Glukhova SI, Kuzin AN, Makarov MA, Makarov SA,
Journal
PubMed ID23864948
The gene expression of mTOR, autophagy-related ULK1, caspase 3, CDK-inhibitor p21, and TNF a was measured in the peripheral blood of osteoarthritic (OA) patients at different stages of the disease aiming to establish a gene expression profile that might indicate the activity of the disease and joint destruction. Whole blood ... More
Genomewide analysis of inherited variation associated with phosphorylation of PI3K/AKT/mTOR signaling proteins.
AuthorsHutz JE, Manning WA, Province MA, McLeod HL,
JournalPLoS One
PubMed ID21949775
While there exists a wealth of information about genetic influences on gene expression, less is known about how inherited variation influences the expression and post-translational modifications of proteins, especially those involved in intracellular signaling. The PI3K/AKT/mTOR signaling pathway contains several such proteins that have been implicated in a number of ... More